Predictors of the development of masked nocturnal hypertension in treated patients of low and moderate cardiovascular risk

Objective. To determine the predictors of the development of masked nocturnal hypertension (HTN) in treated patients of low and moderate cardiovascular risk (CVR). Design and methods. The study included 94 patients with treated HTN of low and moderate CVR without verified cardiovascular diseases. The median age was 42,24 ± 8,08 years. Patients were examined in accordance with the Clinical guidelines on HTN of the Russian Society of Cardiology, approved by the Ministry of Health of the Russian Federation (2020). Patients were divided into two groups depending on the presence or absence of masked nocturnal hypertension. The first group consisted of 54 (57,4 %) patients with masked nocturnal hypertension, the second group — 40 (42,6 %) patients with HTN and target indicators of office blood pressure (BP) and BP according to 24-hour BP monitoring. Results. A direct strong correlation between systolic BP at night and uric acid levels (r = 0,62, p < 0,001), a direct moderate relationship with the cardio-ankle-vascular index (CAVI1) (r = 0,31, p = 0,002), and an inverse moderate relationship with the concentration of high-density lipoprotein cholesterol (HDL cholesterol) (r = -0,47, p < 0,001) were found. When conducting logistic regression analysis and constructing a ROC-curve, the following predictors of the development of masked nocturnal HTN were established: an increase in uric acid > 389 μmol/l, a decrease in HDL < 1,49 mmol/l, an increase in the CAVI1 index > 6,9. Conclusions. In effectively treated patients with HTN with moderate and low CVR, the development of masked nocturnal HTN is associated with an increase in uric acid levels > 389 μmol/l, regardless of sex, an increase in the CAVI1 index > 6,9 and a decrease in HDL cholesterol levels < 1,49 mmol/l.

1. Kobalava ZD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786. In Russian.

2. Kario K, Kanegae H, Tomitani N, Okawara Y, Fujiwara T, Yano Y et al. Nighttime blood pressure measured by home blood pressure monitoring as an independent predictor of cardiovascular events in general practice. Hypertension. 2019;73(6):1240-1248. doi:10.1161/HYPERTENSIONAHA.118.12740

3. Anstey DE, Pugliese D, Abdalla, Bello NA, Givens R, Shimbo D. An update on masked hypertension. Curr Hypertens Rep. 2017;19(12):94. doi:10.1007/s11906-017-0792-4

4. Aung KK, Htay T. Relationship between outpatient clinic and ambulatory blood pressure measurements and mortality. Curr Cardiol Rep. 2019;(21):28. doi:10.1007/s11886-019-1114-z

5. Trudel X, Brisson C, Gilbert-Ouimet M, Duchaine CS, Dalens V, Talbot D et al. Masked hypertension incidence and risk factors in a prospective cohort study. Eur J Prev Cardiol. 2019;(3):231-237. doi:10.1177/2047487318802692

6. Geltser BI, Kotelnikov VN, Vetrova OO, Karpov RS. Masked arterial hypertension: prevalence, pathophysiological determinants and clinical significance. Russian Journal of Cardiology. 2019;24(9):92-98. doi:10.15829/1560-4071-2019-9-92-98. In Russian.

7. Akbarzadeh M, Riahi P, Kolifarhood G, Lanjanian H, Ali-pour N, Najd Hassan Bonab L et al. The AGT epistasis pattern proposed a novel role for ZBED 9 in regulating blood pressure: Tehran Cardiometabolic genetic study (TCGS). Gene. 2022;831:146560. doi:10.1016/j.gene.2022.146560

8. Mizuno H, Hoshide S, Nozue R, Shimbo D, Kario K. Associations of office brachial blood pressure, office central blood pressure, and home brachial blood pressure with arterial stiffness. Blood Press Monit. 2022;27(3):173-179. doi:10.1097/MBP.0000000000000584

9. Lyamina NP, Nali-vaeva AV, Senchikhin VN, Lipchanskaya NP. Masked hypertension in young persons: prevalence, significance of cardiovascular risk factors and prognosis by gender differences. Russian Journal of Cardiology. 2017;4(144):7-12. doi:10.15829/1560-4071-2017-4-7-12. In Russian.

10. Rhee MY, Kim JS, Kim CH, Kim JH, Lee JH, Kim SW et al. Prevalence and characteristics of isolated nocturnal hypertension in the general population. Korean J Intern Med. 2021;36(5):1126-1133. doi:10.3904/kjim.2021.022

11. Kaul U, Bhagwat A, Omboni S, Pancholia AK, Hardas S, Bardoloi N et al. Blood pressure and heart rate related to sex in untreated subjects: the India ABPM study. J Clin Hypertens (Greenwich). 2020;22(7):1154-1162. doi:10.1111/jch.13894

12. Hadjkacem F, Triki F, Frikha H, Charfeddine S, Boujelbene K, Ghorbel D et al. Masked arterial hypertension in patients with type2 diabetes mellitus: prevalence, associated factors and cardiovascular impact. Ann Cardiol Angeiol (Paris). 2022;71(3):136-40. doi:10.1016/j.ancard.2021.10.018. In French.

13. Charfeddine S, Hadj Kacem F, Bahloul A, Triki F, Hammami R, Rebai M et al. Associated factors and sub-clinical myocardial dysfunction in obese patients with masked hypertension. Ann Cardiol Angeiol (Paris). 2022;71(1):6-10. doi:10.1016/j.ancard.2021.05.005. In French.

14. Grassi G, Vanoli J, Facchetti R, Mancia G. Uric acid, hypertensive phenotypes, and organ damage: data from the Pamela Study. Curr Hypertens Rep. 2022;24(2):29-35. doi:10.1007/s11906-022-01174-9

15. Liu C, Qiu D, Zhang M, Hou J, Lin J, Liao H. Association of hyperuricemia and hypertension phenotypes in hypertensive patients without uric acid lowering treatment. Clin Exp Hypertens. 2021;43(6):516-521. doi:10.1080/10641963.2021.1907397

16. Redon P, Maloberti A, Facchetti R, Redon J, Lurbe E, Bombelli M et al. Gender-related differences in serum uric acid in treated hypertensive patients from central and east European countries: findings from the Blood Pressure control rate and CArdiovascular Risk profilE study. J Hypertens. 2019;37(2):380-388. doi:10.1097/HJH.0000000000001908

17. Cai A, Liu L, Siddiqui M, Zhou D, Chen J, Calhoun DA et al. Uric acid Is not associated with blood pressure phenotypes and target organ damage according to blood pressure phenotypes. Am J Hypertens. 2021;34(1):64-72. doi:10.1093/ajh/hpaa130

18. Jaeger BC, Booth JN 3rd, Butler M, Edwards LJ, Lewis CE, Lloyd-Jones DM et al. Development of predictive equations for nocturnal hypertension and nondipping systolic blood pressure. J Am Heart Assoc. 2020;9(2):e013696. doi:10.1161/JAHA.119.013696

19. Allard-Ratick MP, Kindya BR, Khambhati J, Engels MC, Sandesara PB, Rosenson RS et al. HDL: fact, fiction, or function? HDL cholesterol and cardiovascular risk. Eur J Prev Cardiol. 2021;28(2):166-173. doi:10.1177/2047487319848214

20. Kanegae H, Suzuki K, Fukatani K, Ito T, Harada N, Kario K. Highly precise risk prediction model for new-onset hypertension using artificial intelligence techniques. J Clin Hypertens (Greenwich). 2020;22(3):445-450. doi:10.1111/jch.13759

21. Shirai K, Suzuki K, Tsuda S, Shimizu K, Takata M, Yamamoto T et al. Comparison of cardio-ankle vascular Index (CAVI) and CAVI0 in large healthy and hypertensive populations. J Atheroscler Thromb. 2019;26(7):603-615. doi:10.5551/jat.48314

22. Antza C, Vazakidis P, Doundoulakis I, Bouras E, Haidich AB, Stabouli S et al. Masked and white coat hypertension, the double trouble of large arteries: a systematic review and metaanalysis. J Clin Hypertens (Greenwich). 2020;22(5):802-811. doi:10.1111/jch.13876

23. Agarwal R. Albuminuria and masked uncontrolled hypertension in chronic kidney disease. Nephrol Dial Transplant. 2017;32(12):2058-2065. doi:10.1093/ndt/gfw325

24. Yilmaz S, Nar G, Til A, Kaftan A. Morning blood pressure surge and diastolic dysfunction in patients with masked hypertension. Blood Press Monit. 2020;25(3):121-125. doi:10.1097/MBP.0000000000000440